Clinical trial · Interventional
Anesthesia and Circulating Tumor Cells in Breast Cancer
Does Anesthesia Technique Affect the Presence of Circulating Tumor Cells in Primary Breast Carcinoma? A Randomised Controlled Trial.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Serious concern about the role of anesthesia in tumor recurrence has considerably risen over years, but the lack of surrogate markers for tumor spreading made trials addressing this issue difficult to realize. In breast cancer patients CTC positivity has been recently recognized as an independent prognostic factor. In this respect, we postulated that in a first step changes in the number of CTC after general anesthesia would help to determine the effect of anesthesia on this tumor marker.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Female Breast Carcinoma | Female Breast Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Propofol | Drug | — | UNRESOLVED |
| Sevoflurane | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Sevoflurane
- description
- General anesthesia using Sevoflurane
- interventionNames
- Drug: Sevoflurane
- type
- ACTIVE_COMPARATOR
- label
- Propofol
- description
- General anesthesia using propofol TCI
- interventionNames
- Drug: Propofol
Primary outcomes (1)
- measure
- Number of CTC before and after administration of anesthetics
- timeFrame
- 5 days
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion criteria: \> Female * Age 18 to 85 * ASA I-III * Primary breast cancer (TNM stage = T1-3, N0-2, M0) * Primary surgery * Written informed consent Exclusion criteria: * Metastatic breast cancer * Other than primary surgery (recurrence, reconstruction) * Pre-operative chemotherapy or radiotherapy * Auto-immune disease, HIV, other active cancer, age\>85, ASA IV or V * Concomitant regional anesthesia * Chronic opioids medication * Any systemic immunosuppressive therapy * Known hypersensitivity or suspected allergy to propofol, soya or egg proteins * Known hypersensitivity to volatile anesthetics (malignant hyperthermia) * Pregnancy * Breast feeding * Non German-speaking patients * Enrollment in any other clinical trial during the course of this trial, 30 days prior to its beginning or 30 days after its completion
References
Publications (1)
- DERIVEDHovaguimian F, Braun J, Z'graggen BR, Schlapfer M, Dumrese C, Ewald C, Dedes KJ, Fink D, Rolli U, Seeberger M, Tausch C, Papassotiropoulos B, Puhan MA, Beck-Schimmer B. Anesthesia and Circulating Tumor Cells in Primary Breast Cancer Patients: A Randomized Controlled Trial. Anesthesiology. 2020 Sep;133(3):548-558. doi: 10.1097/ALN.0000000000003409. PMID 32568845